Pars Plana Vitrectomy for the Treatment of Uveitis

Christopher R. Henry, Matthias D. Becker, Yongsheng Yang, Janet L Davis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis. Design: Systematic literature review. Methods: A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed. Results: Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Preoperatively, 157 of 300 (52%) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37%) postoperatively. Median use of oral corticosteroids improved from 48% preoperatively to 12% postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56% preoperatively to 36% postoperatively among the reporting studies. Conclusions: Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.

Original languageEnglish (US)
Pages (from-to)142-149
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume190
DOIs
StatePublished - Jun 1 2018

Fingerprint

Temazepam
Vitrectomy
Uveitis
Terminology
Therapeutics
Manuscripts
Anterior Chamber
Macular Edema
Evidence-Based Medicine
Immunosuppressive Agents
Adrenal Cortex Hormones
Guidelines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pars Plana Vitrectomy for the Treatment of Uveitis. / Henry, Christopher R.; Becker, Matthias D.; Yang, Yongsheng; Davis, Janet L.

In: American Journal of Ophthalmology, Vol. 190, 01.06.2018, p. 142-149.

Research output: Contribution to journalArticle

Henry, Christopher R. ; Becker, Matthias D. ; Yang, Yongsheng ; Davis, Janet L. / Pars Plana Vitrectomy for the Treatment of Uveitis. In: American Journal of Ophthalmology. 2018 ; Vol. 190. pp. 142-149.
@article{78bb4988cfc24f01aa3d0603bef4b113,
title = "Pars Plana Vitrectomy for the Treatment of Uveitis",
abstract = "Purpose: To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis. Design: Systematic literature review. Methods: A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed. Results: Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50{\%} of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25{\%} of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10{\%} of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10{\%} of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69{\%}), unchanged in 95 eyes (18{\%}), and worse in 68 eyes (13{\%}) following PPV. Preoperatively, 157 of 300 (52{\%}) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37{\%}) postoperatively. Median use of oral corticosteroids improved from 48{\%} preoperatively to 12{\%} postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56{\%} preoperatively to 36{\%} postoperatively among the reporting studies. Conclusions: Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.",
author = "Henry, {Christopher R.} and Becker, {Matthias D.} and Yongsheng Yang and Davis, {Janet L}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.ajo.2018.03.031",
language = "English (US)",
volume = "190",
pages = "142--149",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Pars Plana Vitrectomy for the Treatment of Uveitis

AU - Henry, Christopher R.

AU - Becker, Matthias D.

AU - Yang, Yongsheng

AU - Davis, Janet L

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose: To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis. Design: Systematic literature review. Methods: A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed. Results: Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Preoperatively, 157 of 300 (52%) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37%) postoperatively. Median use of oral corticosteroids improved from 48% preoperatively to 12% postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56% preoperatively to 36% postoperatively among the reporting studies. Conclusions: Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.

AB - Purpose: To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis. Design: Systematic literature review. Methods: A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed. Results: Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Preoperatively, 157 of 300 (52%) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37%) postoperatively. Median use of oral corticosteroids improved from 48% preoperatively to 12% postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56% preoperatively to 36% postoperatively among the reporting studies. Conclusions: Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.

UR - http://www.scopus.com/inward/record.url?scp=85045568307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045568307&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2018.03.031

DO - 10.1016/j.ajo.2018.03.031

M3 - Article

C2 - 29601822

AN - SCOPUS:85045568307

VL - 190

SP - 142

EP - 149

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -